Symbiotec Pharmalab will launch its ₹1,757-crore IPO from August 24–27, 2026, with a price band of ₹938–988 per share. The minimum bid is 15 shares, requiring an investment of ₹14,820 at the upper price band. The IPO is expected to list on BSE and NSE on September 1, with allotment likely on August 28. At the upper band, the issue values the company at a steep 52 times FY26 diluted EPS.
Chicago Fed President Goolsbee rejects calls for Fed rate cuts to ease US debt burden
Chicago Fed President Austan Goolsbee rejected calls for interest-rate cuts to ease the US government’s debt burden, warning that such a move could fuel inflation